Dyspepsia: General stomach upset, bloating, or a feeling of being uncomfortably full shortly after starting a meal
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4] Ipamorelin significantly increases plasma growth hormone (GH).[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone (GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.[3] Ipamorelin Peptide is under active investigation in a number of cell culture and animal models
Gastrointestinal side effects from GLP-1 medications (nausea, diarrhea) can complicate absorption of oral DMARDs or mask early signs of disease flare
For split dosing, which maintains the same total weekly dose, mathematical models suggest efficacy maintenance of 80% to 95%
Immediate Nutrient Absorption Boosts Energy Levels Immunity Support Muscle Recovery Mental Clarity Tailored to meet your needs Focused On You As our valued patient, you are at the center of everything we do and that will never change
